Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT00520871 Completed - Clinical trials for Cardiovascular Disease

The Water-Blueberry Study

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

We will study the effect of supplementation of 1 L blueberry juice to participants with at least one elevated cardiovasculat risk factor.

NCT ID: NCT00520819 Completed - Clinical trials for Cardiovascular Disease

Oslo Antioxidant Study

Start date: February 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to test whether increasing the total intake of antioxidants to middle-aged smoking men increases the antioxidant defence, reduces oxidative damage, and improves biomarkers for oxidative stress. The secondary objectives is to test whether this strategy improves other cardiovascular risk markers including platelet function, lipid levels, inflammation, and markers of endothelial damage.

NCT ID: NCT00520195 Completed - Clinical trials for Cardiovascular Diseases

Stair Instead of Elevator Use at Work: Cardiovascular Primary Preventive Effects on Hospital Employees.

Start date: March 2007
Phase: N/A
Study type: Interventional

This is an intervention study which evaluates the cardiovascular primary preventive effects of using stairs instead of elevators at the worksite during a 12-weeks period. We hypothesize that stair-climbing during working hours can meet the daily amount of physical activity recommended by current public health guidelines.

NCT ID: NCT00517686 Completed - Clinical trials for Cardiovascular Disease (CVD) Risk Factors

Feedback of Treatment Intensification Data to Reduce Cardiovascular Disease Risk (FIT)

FIT
Start date: July 2008
Phase: N/A
Study type: Interventional

The primary research question of this study is to determine whether measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD) can improve rates of treatment intensification and reduce levels of poorly controlled systolic blood pressure, LDL-c, and A1c.

NCT ID: NCT00517478 Not yet recruiting - Clinical trials for Myocardial Infarction

Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI

Start date: August 2007
Phase: N/A
Study type: Observational

Determine usefulness of thromboelastography (TEG) as a valuable tool in ex-vivo assessing platelet response to aspirin and clopidogrel (dual) treatment and on-treatment platelet reactivity during acute ST segment elevation myocardial infarction (STEMI) in an acute phase during primary PCI (PPCI) and also during recovery been on maintenance medical therapy and to determine the correlation between platelet response to clopidogrel treatment and the outcome of patients.

NCT ID: NCT00516880 Recruiting - Clinical trials for Cardiovascular Diseases

Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?

Start date: March 2006
Phase: N/A
Study type: Interventional

Peritoneal dialysis patients are at increased risk of cardiovascular morbidity and mortality and are related to the presence of accelerated atherosclerosis. Our recent data showed that inflammation predicts mortality and cardiovascular death, independent of other cardiovascular risk factors in peritoneal dialysis patients. As a considerable proportion of peritoneal dialysis patients showed evidence of inflammation, it raises an important question as to whether anti-inflammatory treatment has any cardiovascular and survival benefit in these patients. The peroxisome proliferator-activated receptor-gamma (PPAR-g) agonist is a class of drug with insulin sensitizing property. Recent experimental and clinical studies demonstrated that this class of drug has anti-inflammatory and anti-atherosclerotic properties other than insulin sensitizing effect in type 2 diabetics. We therefore hypothesize that modulation of the PPAR-g activity may be a novel therapeutic strategy for reducing inflammation and retarding the progression of atherosclerosis and possibly lowering mortality in our peritoneal dialysis patients.

NCT ID: NCT00516594 Completed - Clinical trials for Cardiovascular Disease

The Effect of Altering Colonic Microflora After Fiber (FOS) Consumption

Start date: n/a
Phase: Phase 2
Study type: Interventional

Our antibiotic studies indicated that cholesterol lowering was seen when fecal bifidobacterial counts were increased. Due to the dangers associated with prolonged antibiotic use we have been funded by the Heart and Stroke Foundation to see if gut bacteria can be modified by non-antibiotic means. Inulin a dietary fiber found in artichokes, chicory, leaks, onion, etc., (which also produces flatulence) has been shown to increase bifidobacteria and also appears to lower serum cholesterol. We will therefore test the fiber to determine its effectiveness in lowering serum cholesterol and whether it can be used to maximize the cholesterol-lowering effects of soy protein foods and viscous fiber foods (e.g. oats and psyllium).

NCT ID: NCT00515541 Completed - Clinical trials for Cardiovascular Disease

Lovaza's Effect on the Activation of Platelets

LEAP
Start date: September 2007
Phase: Phase 2
Study type: Interventional

This study is to determine the effects of Lovaza in platelet function studies

NCT ID: NCT00513903 Completed - Clinical trials for Cardiovascular Diseases

Expanding the Role of Pharmacists in Treating Persons With Cardiovascular or Lung Diseases

IowaCOC
Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study will test whether enhanced continuity of pharmacy care that includes increased communication between inpatient and outpatient settings will improve the appropriateness of medication therapy and reduce the number of serious adverse drug events, hospitalizations and unscheduled office visits in vulnerable patients with cardiovascular disease, pulmonary disease or diabetes.

NCT ID: NCT00511420 Completed - Clinical trials for Cardiovascular Diseases

Effects of Cocoa Products on Cardiovascular Disease Risk Factors

CoCD
Start date: April 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of optimized composition chocolates that include natural ingredients with demonstrated biological activity are observed cardioprotectores effects in the human.